Publication:
18F-FDG PET/CT mean suv and metabolic tumor volume for mean survival time in non-small cell lung cancer

dc.contributor.coauthorKurtipek, Ercan
dc.contributor.coauthorÇaycı, Mustafa
dc.contributor.coauthorDüzgün, Nuri
dc.contributor.coauthorEsme, Hıdır
dc.contributor.coauthorTerzi, Yüksel
dc.contributor.coauthorBakdık, Süleyman
dc.contributor.coauthorÜnlü, Yaşar
dc.contributor.coauthorBurnik, Cengiz
dc.contributor.coauthorBekçi, Taha Tahir
dc.contributor.departmentN/A
dc.contributor.kuauthorAygün, Murat Serhat
dc.contributor.kuprofileTeaching Faculty
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.contributor.unitKoç University Hospital
dc.contributor.yokid291692
dc.date.accessioned2024-11-09T23:17:53Z
dc.date.issued2015
dc.description.abstractObjective: The study was designed to determine the relationship between survival time of standardized uptake value (SUVmax and SUVmean) and metabolic tumor volume (MTV) in patients with non-small cell lung cancer (NSCLC), and examine the impact of demographic, clinical, and radiological data of these patients on survival. Materials and Methods: We performed a retrospective analysis of the records of 79 patients with NSCLC who presented to our hospital between May 2010 and March 2013, received a final diagnosis, and underwent 18F-FDG PET/CT for staging. Clinical, radiological, and 18F-FDG PET/CT parameters with an impact on prognosis such as the SUVmax of the primary tumor as calculated by the volumetric region of interest in the 18F-FDG PET/CT scans during initial diagnosis, mean SUV of the tumor, and MTV obtained with a threshold of SUVmax greater than 2.5 were recorded and statistically analyzed. A statistical analysis was carried out based on the clinical, radiological, and PET/CT findings of the patients who were divided into 2 groups: survivors and nonsurvivors. Results: Seventy patients (88.6%) were men, and 9 (11.4%) were women. The mean age was 63.65 ± 11.51 years in the nonsurvivor group (n = 40) versus 62.74 ± 10.60 years in the survivor group (n = 39) (Table 1). The mean survival time from diagnosis was 7.9 ± 6.52 months in the nonsurvivor group versus 14.09 ± 7.41 months in the survivor group. The mean survival time was 12.9 ± 7.9 months for those aged 60 or younger, whereas it was 9.9 ± 7.2 years for those aged 60 or older. According to the Cox regression analysis, higher MTV [relative risk (RR), 1.006; P = 0.03] and mean SUVmax (mSUV) (RR, 1.302; P = 0.03) had a significant impact on shortening of the mean survival time. However, no statistical significance was reached for SUVmax measurements (RR, 0.970; P = 0.39). Furthermore, there was a significant relationship between increased tumor size (andlt;2 cm, 2-4 cm, and ≥4 cm) and shortened mean survival time (P = 0.03). Conclusion: The present study showed that MTV and mSUV of FDG PET/CT scans of the tumor, but not SUVmax, had a significant impact on survival time of patients with NSCLC. Based on this result, we believe that we might have more accurate information about the survival time of our patients if we also evaluate mSUV and MTV in combination with mSUV, which is frequently used for diagnosis and monitoring of patients with NSCLC during our daily practice. © 2015 Wolters Kluwer Health, Inc. All rights reserved.
dc.description.indexedbyWoS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue6
dc.description.openaccessYES
dc.description.publisherscopeInternational
dc.description.volume40
dc.identifier.doi10.1097/RLU.0000000000000740
dc.identifier.issn0363-9762
dc.identifier.linkhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84929907767anddoi=10.1097%2fRLU.0000000000000740andpartnerID=40andmd5=5f6ff04cb2a75845de8ad5cfe63f8efd
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-84929907767
dc.identifier.urihttp://dx.doi.org/10.1097/RLU.0000000000000740
dc.identifier.urihttps://hdl.handle.net/20.500.14288/10273
dc.identifier.wos354883000015
dc.keywords18F-fluorodeoxyglucose (FDG)
dc.keywordsMetabolic tumor volume
dc.keywordsNon-small cell lung cancer fluorodeoxyglucose F 18
dc.keywordsRadiopharmaceutical agent
dc.keywordsAdult
dc.keywordsAged
dc.keywordsArticle
dc.keywordsCancer Diagnosis
dc.keywordsCancer patient
dc.keywordsCancer prognosis
dc.keywordsCancer survival
dc.keywordsCancer survivor
dc.keywordsClinical laboratory
dc.keywordsComputer assisted emission tomography
dc.keywordsCorrelational study
dc.keywordsDemography
dc.keywordsFemale
dc.keywordsFollow up
dc.keywordsHuman
dc.keywordsMajor clinical study
dc.keywordsCarcinoma, Non-Small-Cell Lung
dc.keywordsFemale
dc.keywordsFluorodeoxyglucose F18
dc.languageEnglish
dc.publisherLippincott Williams and Wilkins
dc.sourceClinical Nuclear Medicine
dc.subjectMedicine
dc.title18F-FDG PET/CT mean suv and metabolic tumor volume for mean survival time in non-small cell lung cancer
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.authorid0000-0003-4112-0618
local.contributor.kuauthorAygün, Murat Serhat

Files